Alpha Cognition Inc. Financing Cash Flow
Alpha Cognition Inc. (ACOG) reported Financing Cash Flow of $800 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- Alpha Cognition Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- Alpha Cognition Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $800.00.
- Alpha Cognition Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $37.70M, a 19.99% decline year-over-year.
- Alpha Cognition Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.36M, a 67.33% decline year-over-year.
- Alpha Cognition Inc. net cash provided by (used in) financing activities for fiscal 2025 was $38.21M, a 30.33% decline from fiscal 2024.
- Alpha Cognition Inc. net cash provided by (used in) financing activities for fiscal 2024 was $54.85M, a 566.49% increase from fiscal 2023.
- Alpha Cognition Inc. net cash provided by (used in) financing activities for fiscal 2023 was $8.23M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $800.00 10-Q · filed 2026-08-13 | $37.70M derived: sum of 3 quarters · filed 2026-08-13 | $39.06M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $800.00 10-Q · filed 2026-05-14 | $37.70M derived: sum of 2 quarters · filed 2026-05-14 | $39.06M derived: sum of 3 quarters · filed 2026-05-14 | $39.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $37.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $39.06M derived: sum of 2 quarters · filed 2026-03-31 | $39.05M derived: sum of 3 quarters · filed 2026-08-13 | $38.21M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.35M derived: sum of 2 quarters · filed 2026-08-13 | $513.13K 10-Q · filed 2025-11-13 | $47.63M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$10.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$845.11K 10-Q · filed 2026-08-13 | $46.28M derived: sum of 3 quarters · filed 2026-08-13 | $50.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$834.30K 10-Q · filed 2026-05-14 | $46.29M derived: sum of 2 quarters · filed 2026-05-14 | $50.44M derived: sum of 3 quarters · filed 2026-05-14 | $50.62M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $47.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $51.28M derived: sum of 2 quarters · filed 2026-03-31 | $51.45M derived: sum of 3 quarters · filed 2026-03-31 | $54.85M 10-K · filed 2026-03-31 |
| 2024-09-30 | $4.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.33M derived: sum of 2 quarters · filed 2025-11-13 | $7.73M 10-Q · filed 2025-11-13 | $10.35M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $173.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.57M 10-Q · filed 2025-08-14 | $6.19M derived: sum of 3 quarters · filed 2025-08-14 | $7.50M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $3.40M 10-Q · filed 2025-05-15 | $6.02M derived: sum of 2 quarters · filed 2025-05-15 | $7.32M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.92M derived: sum of 2 quarters · filed 2025-03-31 | $8.23M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $5.61M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $4.31M 10-Q · filed 2024-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |